 |
KaloBios Pharmaceuticals, Inc. Raises $8.2 Million in Private Placement
Dec 3, 2015
|
25.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Dec. 3, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), today announced it has entered definitive agreements with institutional and accredited investors in connection with a private placement, or PIPE financing. Upon closing of the transaction, the Company will receive gross proceeds of approximately...
|
|
KaloBios Announces Agreement to Acquire Benznidazole Program for the Treatment of Chagas Disease
Dec 3, 2015
|
28.2 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Dec. 3, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), today announced that it has signed an agreement to acquire a benznidazole program for the treatment of Chagas Disease from Savant Neglected Diseases, LLC, a privately-held specialty pharmaceutical company. Under the terms of the agreement, KaloB...
|
|
KaloBios Announces Management Additions
Dec 3, 2015
|
25.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Dec. 3, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), today announced that Patrick Crutcher has been appointed Head of Business Development, Chris Thorn has been appointed interim Chief Financial Officer and Edward Painter has been appointed Head of Communications and Investor Relations.
...
|
|
KaloBios Pharmaceuticals, Inc. Appoints Martin Shkreli CEO and Announces New Financing
Nov 19, 2015
|
27.1 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), today announced that an investor group led by Martin Shkreli, the Founder and Chief Executive Officer of Turing Pharmaceuticals AG, has acquired 70% of its outstanding shares. KaloBios also announced the appointment of Martin Shkreli to the pos...
|
|
KaloBios Confirms Communications with Majority Shareholder Group
Nov 18, 2015
|
27.5 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) today announced that it has been informed that an investor group comprised of Martin Shkreli and associates together have acquired more than 50% of the outstanding shares of KaloBios, and that the company is in discussions with Mr. Shkreli regard...
|
|
KaloBios to Wind Down Operations
Nov 13, 2015
|
26.4 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) today announced that it will wind down its operations and that it has engaged the Brenner Group to lead those efforts.
"Recent discussions around a number of possible strategic transactions have ended, and as a result, the company bel...
|
|
KaloBios to Reduce Workforce, Explore Strategic Alternatives
Nov 5, 2015
|
28.3 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Nov. 5, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) today announced that it will reduce its workforce as part of a plan to reduce operating costs. This action will reduce the company's workforce by approximately 17 employees (or 61%), and will focus the company's resources on the ongoing developmen...
|
|
KaloBios to Present at 14th Annual BIO Investor Forum
Oct 15, 2015
|
28.2 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that it will present at the 14th Annual BIO Investor Forum in San Francisco, California on October 20, 2015.
Herb C. Cross, the company's Chief Financial Officer and Interim Chief Executive Officer, will provide an up...
|
|
KaloBios Reports Second Quarter Financial Results and Provides Clinical Update
Aug 10, 2015
|
36.7 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), a monoclonal antibody company focused on oncology, today announced its financial results for the second quarter of 2015 and provided an update on its clinical development progress.
Second Quarter 2015 Financial Results
Net lo...
|
|
KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia
Jul 29, 2015
|
36.9 KB |
|
| |
SOUTH SAN FRANCISCO, July 29, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), a monoclonal antibody company focused on developing innovative therapies to benefit patients with diseases of unmet medical need, with a focus on oncology, announced today that the U.S. Food and Drug Administration (FDA) has cleared the company's inves...
|
|
KaloBios Regains Compliance with NASDAQ Minimum Bid Price Requirement
Jul 29, 2015
|
35.4 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., July 29, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), a monoclonal antibody company focused on developing innovative therapies to benefit patients with diseases of unmet medical need, with a focus on oncology, announced today that it received a formal determination letter from The NASDAQ Stock Mar...
|
|
KaloBios Announces Shareholders and Board of Directors Approval of Reverse Stock Split
Jul 13, 2015
|
28.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., July 13, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), a monoclonal antibody company focused on developing innovative therapies to benefit patients with diseases of unmet medical need, with a focus on oncology, announced today that it will effect a reverse stock split at a ratio of one share of new...
|
|
KaloBios to Present at the JMP Securities Life Sciences Conference
Jun 17, 2015
|
28.5 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., June 17, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that it will present at the JMP Securities Life Sciences Conference 2015 in New York City, New York on June 23, 2015.
Herb C. Cross, the company's Interim Chief Executive Officer, will provide an update on KaloBios' o...
|
|
KaloBios Appoints Ronald A. Martell Executive Chairman
May 28, 2015
|
28.9 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., May 28, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the appointment of Ronald A. Martell, to the position of Executive Chairman. Mr. Martell currently serves as a member of the KaloBios Board of Directors. In this new role, he will work directly with the company's senior management...
|
|
KaloBios Reports First Quarter 2015 Financial Results
May 11, 2015
|
34.1 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., May 11, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today reported its financial results for the first quarter of 2015.
Net loss for the quarter ended March 31, 2015 was $9.6 million or $0.29 per common share, as compared to $10.4 million or $0.32 per common share for the same period i...
|
|
KaloBios Elects Ronald A. Martell to Board of Directors
Apr 22, 2015
|
28.5 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., April 22, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the election of veteran biopharmaceutical industry executive, Ronald A. Martell, to the KaloBios Board of Directors.
"Ron is a seasoned biotechnology industry executive with significant expertise in clinical develo...
|
|
KaloBios to Present at the 14th Annual Needham Healthcare Conference
Apr 6, 2015
|
29.0 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., April 6, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that it will present at the 14th Annual Needham Healthcare Conference in New York City, New York on April 14, 2015.
Herb Cross, Interim Chief Executive Officer and Chief Financial Officer of KaloBios, will provide an ...
|
|
KaloBios Reports Fourth Quarter 2014 Financial Results
Mar 16, 2015
|
42.6 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., March 16, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today reported its financial results for the fiscal year 2014.
Net loss for the fiscal year ended December 31, 2014 was $38.0 million or $1.15 per common share, as compared to $41.9 million or $1.73 per common share for 2013.
...
|
|
KaloBios Announces Upcoming Investor Conference Participation
Feb 3, 2015
|
30.5 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Feb. 3, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that it will present at the BIO CEO & Investor Conference, and will participate in an analyst-led fireside chat at the Leerink Partners 2015 Global Healthcare Conference next week in New York City, New York.
Herb Cross...
|
|
KaloBios Announces Retirement of David W. Pritchard, President and Chief Executive Officer
Jan 8, 2015
|
29.9 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Jan. 8, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that David W. Pritchard, president and chief executive officer, has decided to retire, effective immediately, and has also resigned his position as a member of the company's Board of Directors. The company has named Herb C. Cross,...
|
|
|
